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irritated 7.9%, persistent crying over 3hours 0.5%, and drowsi-
ness/sleepiness 0.5%. Eleven serious adverse events were reported,
mostly infections of the lower respiratory tract; none were consid-
ered related to Quinvaxem®.304 15th ICID Abstracts / International Journa
ype: Poster Presentation
inal Abstract Number: 48.010
ession: Vaccines & Vaccine Development
ate: Friday, June 15, 2012
ime: 12:45-14:15
oom: Poster & Exhibition Area
afety and reactogenicity of the 10-valent pneumococcal non-
ypeable Haemophilus inﬂuenzae protein D conjugate vaccine
PHiD-CV) co-administered with DTPa-HBV-IPV/Hib in Viet-
amese infants
.N. Huu1,∗, N.T. Toan1, H.M. Tuan2, H.L. Viet2, P.L. Thanh Binh2,
.-W. Yu3, F. Shaﬁ4, A. Habib3, D. Borys3
Pasteur Institute, Ho Chi Minh City, Viet Nam
Children’s Hospital 2, Ho Chi Minh City, Viet Nam
GlaxoSmithKline Biologicals, Wavre, Belgium
GlaxoSmithKline Pharmaceuticals, Bangalore, India
Background: Pneumococcal infections are a major cause of
nfant mortality/morbidity in developing countries. This study
ssessed the safety and reactogenicity of PHiD-CV (SynﬂorixTM;
laxoSmithKline Biologicals) co-administered with DTPa-HBV-
PV/Hib (Infanrix hexaTM; GlaxoSmithKline Biologicals) to infants
n Vietnam, a developing country setting.
Methods: In this phase III, single centre, open-label study
NCT01153841), infants were randomised (2:1) to receive 3-dose
rimaryvaccinationat 2, 3 and4monthsof agewitheither PHiD-CV
o-administered with DTPa-HBV-IPV/Hib (PHiD-CV/Hx group), or
TPa-HBV-IPV/Hib alone (Control group). Solicited and unsolicited
dverse events (AEs) (any and grade 3)were recordedwithin 4 days
nd31days post-vaccination, respectively. SeriousAEs (SAEs)were
ecorded throughout the study. Safety analyseswere carried out on
he total vaccinated cohort.
Results: Between February and July 2011, 300 infants were
nrolled; 298 received betweenone and three vaccine doses (PHiD-
V/Hx group: n=199; Control group: n=99). Within 31 days
ost-vaccination, 8.2% and 3.0% of overall doses in the PHiD-CV/Hx
nd Control groups, respectively, were followed by ≥1 grade 3 AE
solicited and/or unsolicited, local and/or general). Within 4 days
ost-vaccination, the most frequent solicited local symptom was
ain (PHiD-CV/Hx group: 48.9% of doses; Control group: 31.0% of
oses) and the most frequent solicited general symptom was irri-
ability (PHiD-CV/Hx group: 58.0% of doses; Control group: 40.4% of
oses). Themost frequent grade 3 local symptomwas pain; follow-
ng 6.5% and 1.0% of doses in the PHiD-CV/Hx and Control groups,
espectively. Grade 3 solicited general symptoms were uncommon
n both groups (PHiD-CV/Hx group: ≤1.9% of doses; Control group:
0.3% of doses). Unsolicited symptoms were reported following
2.3% and 14.8% of doses in the PHiD-CV/Hx and Control groups,
espectively. Grade 3 unsolicited symptoms were reported follow-
ng ≤0.3% of doses; none were considered related to vaccination.
ifteen infants reported ≥1 SAE (PHiD-CV/Hx group: 9/199; Con-
rol group: 6/99); none were fatal; none were considered related
o vaccination.
Conclusion: A PHiD-CV 3-dose primary vaccination, co-
dministered with DTPa-HBV-IPV/Hib at 2, 3 and 4 months of age
as well tolerated by Vietnamese infants. PHiD-CV reactogenicity
as comparable to that observed in other South-East Asian popu-
ations.1,2
1Chevallier PIDJ 2009;28:S109-18.
2Kim PIDJ 2011;30:e235-43.
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Assessment of the immunogenicity and safety of Quinvaxem®
(DTwP-HepB- Hib) against diphtheria, pertussis, tetanus, hep-
atitis B and diseases caused by H. inﬂuenzae among healthy
Vietnamese children
T.N. Huu1, N.T.M. Phuong2, N.T. Toan3, H.V. Thang4, V.T.Q.
Huong2, C.H. Nghia2, N.V. Hoang5, P.V. Luan6, P.H. Thai7, C.
Jica8,∗
1 Institute Pasteur, Ho Chi Minh City, Viet Nam
2 Pasteur Institute, HCM City, Viet Nam
3 Pasteur Institute, Ho Chi Minh City, Viet Nam
4 Pasteur Institute, HCM City, Viet Nam
5 Preventive Medicine Centre of Long An province, Long An, Viet Nam
6 Preventive Medicine Centre of Ben Luc district, Ben Luc, Viet Nam
7 Ben Luc district Hospital, Long An Province, Long An, Viet Nam
8 Crucell Switzerland, Berne, Switzerland
Background: An open, uncontrolled, single center, interven-
tional study, performed between March 2010 and September
2011 in nine villages in Long An province, Vietnam, to assess the
immunogenicity and safety of Quinvaxem® (DTwP-HepB-Hib) in
131 healthy children who had not previously received DTP vacci-
nation.
Methods: Subjects received three doses of Quinvaxem® using a
2-3-4 month schedule according to the local EPI. Immunogenicity
blood sampleswere collected at baseline, onemonth after the third
injection and one year after the ﬁrst injection. Solicited local and
systemic adverse events (AEs) and unsolicited AEs were collected
by active monitoring up to 30minutes post-vaccination and at 6,
24 and 48hours, 3 to 7 days and 28 days.
Results: Seroprotection rates were deﬁned as the percentage of
subjects with titers as follows: anti-diphtheria ≥0.1 IU/mL, anti-
tetanus ≥0.1 IU/mL, Hib ≥0.15g/mL, anti-HBs ≥10mIU/mL, and
anti-B. pertussis (seroconversion)≥20EU/mLor a four-fold increase
compared with baseline titers.
One month after the third dose, seroprotection rates for
hepatitis B and for diphtheria were both 93.1%, for tetanus
98.5%, for pertussis 99.2% (seroconversion) and for Hib was 100%
(≥0.15g/mL); 99.2% attained a Hib concentration of ≥1.0g/mL.
Twelvemonths after theﬁrst vaccination seroprotection rateswere
lower: hepatitis B 76.7%, diphtheria 88.4%, tetanus 82.2%, Hib 97.7%
(≥0.15g/mL) and pertussis 49.6% (seroconversion). This decline
in immunogenicity is in line with published data and is the reason
why some countries opt for a booster dose.
Overall incidence rates of swelling (≥5mm), redness (≥5mm),
and pain at the injection site were 5.6%, 2.8%, and 4.1%, respec-
tively (for all 392 injections). The incidence rates of systemic
AEs were: fever (38–38.9 ◦C, auxillary) 15.8%, fever (>39 ◦C) 2.6%,
refusal to suckle 2.6%, rash 0.3%, vomiting 1.0%, diarrhea 3.0%, easily
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ception regarding vaccines and cultural concerns such as perceived
relationship of vaccine with family planning.
http://dx.doi.org/10.1016/j.ijid.2012.05.99515th ICID Abstracts / International Journa
Conclusion: Quinvaxem® was immunogenic and well toler-
ted when administered according to a 2-3-4 month regimen in
ietnamese infants; this study conﬁrms the excellent efﬁcacy and
afety proﬁle of Quinvaxem®.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.993
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he Global Meningococcal Initiative (GMI): efforts to prevent
nd control meningococcal disease in India
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utta6, V. Yewale7, R. Borrow8, L. Harrison9
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Background: The Global Meningococcal Initiative (GMI) is led
y international experts in meningococcal immunology, epidemi-
logy, vaccinology, and public health. The goal is to prevent
eningococcal disease (MD) through education, research, and vac-
ination.
Methods: In January 2012, the GMI met with Indian experts to
eview India’s MD burden and to explore MD prevention/control
trategies.
Results: Neisseria meningitidis is the third commonest cause
f sporadic bacterial meningitis in children <5 years, with a
igher prevalence in temperate northern versus tropical southern
egions. Actual incidence is underestimated, due to a conﬂuence
f fractured surveillance, rampant antibiotic use, and insufﬁcient
icrobiological support for diagnosis. India experiences occasional
approximately every 20 years)—but large—MD outbreaks caused
xclusively by serogroup A, with only rare reports of serogroups
and C. There have been unusual increases in the number of
D outbreaks in Delhi, Meghalaya, and Tripura since 2005. Out-
reakmanagement involvesmandatory case reporting by hospitals
n Delhi, temporarily strengthening laboratory diagnostics and
hemoprophylaxis of close contacts/high-risk groups, and limited
eactive vaccination. Currently, only meningococcal polysaccha-
ide vaccines are available in India and have successfully contained
he Meghalaya and Tripura outbreaks. However, an Indian facil-
ty is manufacturing a serogroup A conjugate vaccine for use in
ub-Saharan Africa. The GMI recommends replacement of polysac-
haride vaccines with conjugate vaccines—without necessarily
hanging current indications. Although routine immunization is
ndorsed in some settings, costs and data limitations make such
n effort not presently feasible in India. To improve surveillance,
nd thus understanding of true MD burden, the GMI recommends
1) soliciting existing reference centers to generate diagnostic data
sing RT-PCR, (2) wider use of latex agglutination tests on CSF for
onﬁrmingmeningitis, and (3) initiating carriage and seroepidemi-fectious Diseases 16S (2012) e158–e316 e305
ological studies. Until robust data are available, it will be difﬁcult
to justify prioritizing MD for routine vaccination.
Conclusion: MD burden in India is underestimated, and more
robust surveillance data are needed. Control efforts should focus
on expanding surveillance and educating physicians and regulators
of biological interventions on the importance of MD, its diagnosis,
and the need for quality data. Conjugate vaccines should be the
vaccines of choice for outbreak control and immunization of high-
risk persons.
http://dx.doi.org/10.1016/j.ijid.2012.05.994
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Factors affecting participation in a typhoid vaccine trail in
Pakistan
M.I. Khan
International Vaccine Institute, Seoul, Korea, Republic of
Background: Participation in vaccination campaigns has
increased worldwide. However, behavioral and socio-cultural bar-
riers continue to exist in developing countries.
Methods: The study was designed to understand perceptions of
typhoid fever, gauge level of interest in a vaccine against thedisease
and experiences of participants in vaccine trial. A pre-vaccination
socio-behavioral survey was conducted on a random sample of
502 householdswith children (2-16 years) of them295 households
were accessible after the vaccination campaign. Refusal rate in our
sample was low compared to 15% in the vaccination campaign,
so to explore factors for non-participation 200 randomly selected
households were visited.
Results: Non-participants had fewer household members with
a history of typhoid fever, than participants (p <0.01); Non-
participants were less aware of anyone suffering from a serious
case of typhoid fever, than participants (p <0.01); Non-participants
were less satisﬁed with the information given them about the trial
(p <0.01). Non-participants were less satisﬁed with the trial logis-
tics (p <0.01); Non-participants were less interested in a vaccine
against typhoid fever for their children in the future (p <0.01).
Conclusion: Typhoid fever is a paediatric illness in Pakistan.
Perceived severity and vulnerability in contracting the disease and
experienceswith the illness inﬂuences decisions to take vaccine for
a disease. However, it is very imperative to consider prevailing per-
